We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01434693
Recruitment Status : Completed
First Posted : September 15, 2011
Results First Posted : May 20, 2013
Last Update Posted : May 20, 2013
Information provided by (Responsible Party):
Coronado Biosciences, Inc.

Brief Summary:
This is a sequential dose-escalation (with up to 3 dose levels of TSO, ie, 500, 2500, and 7500 TSO), randomized (within each of 3 periods, with a ratio of 3:1 for TSO to placebo), double-blind, placebo-controlled study to evaluate the safety of a single dose of oral CNDO-201 Trichuris suis ova suspension, as compared to placebo, in patients with Crohn's Disease.

Condition or disease Intervention/treatment Phase
Crohn's Disease Biological: Trichuris suis ova Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Sequential Dose-Escalation, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Single Doses of 3 Different Doses of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease
Study Start Date : November 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: TSO 500 Biological: Trichuris suis ova
single dose

Experimental: TSO 2500 Biological: Trichuris suis ova
single dose

Experimental: TSO 7500 Biological: Trichuris suis ova
single dose

Placebo Comparator: Placebo
single dose
Other: Placebo

Primary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: 6 mo ]
    Comparison of safety and tolerability was performed across the dose levels by evaluating the post-dose tolerability of TSO in patients with Crohn's Disease via incidence of adverse events (i.e. # events) with a specific focus on reported gastrointestinal signs and symptoms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females, 18 to 55 years old.
  2. Patient has confirmed diagnosis of Crohn's Disease by established criteria with a minimum disease duration of 3 months.
  3. If patient is using concomitant medications, the dose/regimen is stable and remains stable for the two weeks of close observation following TSO administration. Concomitant medications may include: 1) Oral sulfasalazine, mesalazine (5-ASA), or mesalazine derivative, if receiving it for >6 weeks and if receiving the same dose for at least 4 weeks; 2) Oral prednisone up to 15 mg/day, if receiving it for >4 weeks and if receiving the same dose for at least 2 weeks; and 3) Azathioprine or 6-mercaptopurine if receiving it for >3 months and if receiving the same dose for at least 8 weeks.
  4. Hemoglobin ≥ 12 g/dL at screening.
  5. Normal white blood cell count and normal lymphocyte count at screening.
  6. Platelet count > lower limit of normal at screening.
  7. For females of childbearing potential, negative serum pregnancy test during the screening period, not breastfeeding for study duration, and willingness to use accepted forms of reliable birth control for study duration [including bilateral tubal ligation, use of oral contraceptives, double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera®, hormonal implants, partner vasectomy, and total abstinence]. Pregnancy tests are not required (indicate "N/A") for males or females not of childbearing potential (post-menopausal with last menstrual period >1 year ago or total hysterectomy).
  8. Patient must have the ability to provide informed consent.

Exclusion Criteria:

  1. Patient with ulcerative colitis, indeterminate colitis, or ulcerative proctitis.
  2. Bowel surgery in past 6 months.
  3. Resection of more than 50 cm of the ileum.
  4. Ileostomy colostomy.
  5. Septic complications.
  6. Patient who is hospitalized or exhibiting signs of toxicity (sepsis), has significant or multiple strictures, or impending obstruction (as evidenced by abdominal distension, severe abdominal tenderness, fever, nausea, vomiting, or tachycardia) or anticipating a need for blood transfusion for gastrointestinal bleeding or in whom surgical intervention may be imminent.
  7. Patient with gastrointestinal abscess, perforation, active draining fistulae or fistulae that are considered clinically significant or perianal lesions.
  8. Patient with history of colorectal cancer or colorectal dysplasia.
  9. Parenteral or tube feeding.
  10. Patient with evidence of infectious colitis, e.g., Clostridium difficile, Amoebiasis, Giardia lamblia or stools positive for other enteric pathogens, ova or parasites at Screening.
  11. Female patient who is pregnant or breastfeeding or wishing to become pregnant during study participation or unwilling to use birth control.
  12. Patient with serum creatinine ≥ 2.0 mg/dL; blood urea nitrogen >40 mg/dL; alkaline phosphatase > 250 U/L; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 100 U/L; or total bilirubin >1.5 mg/dL.
  13. Patient with white blood count <5,000 or >15,000/mm3; platelet count <150,000 per μl; or iron or vitamin B12 deficiency. Correction of lab exclusion is allowed provided that medical condition is not deemed to put patient at risk and stability of result is sustained for a minimum of 30 days.
  14. Patient with active hepatitis B virus, hepatitis C virus, liver cirrhosis or portal hypertension, cytomegalovirus, Epstein Barr Virus or herpes simplex virus or is known to be human immunodeficiency virus (HIV) positive.
  15. Patient with primary sclerosing cholangitis.
  16. Patient with active malignancy or treatment with anticancer drugs in the past 5 years.
  17. Patient received cyclosporine, anti-TNF or other immunomodulatory agents other than azathioprine/6-mercaptopurine 12 weeks prior to Screening.
  18. Patient received methotrexate 4 weeks prior to Screening.
  19. Patient received metronidazole 2 weeks prior to Screening.
  20. Patient received non-steroidal anti-inflammatory drugs (NSAIDS) within 2 weeks before Baseline visit for more than 3 consecutive days, except acetylsalicylic acid ≤ 350 mg/d which is allowed.
  21. Patient received antibiotic, antifungal or antiparasitic medication in the last 2 weeks prior to Screening and/or would potentially require this during the study treatment period.
  22. Patient with history of drug or alcohol abuse within 6 months prior to Screening.
  23. Patient with evidence of poor compliance with medical advice and instruction including diet or medication.
  24. Patient is unable or unwilling to swallow study medication suspension.
  25. Patient with a significant medical condition which puts the patient at risk for study participation and/or for any reason is considered by the Investigator to be an unsuitable candidate to receive CNDO-201 TSO or is potentially put at risk by study procedures.
  26. Patients who has participated in another clinical trial within 30 days of Screening for this trial and/or any experimental treatment for this population.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01434693

Layout table for location information
United States, California
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
United States, Florida
Borland-Groover Clinic
Jacksonville, Florida, United States, 32256
Shafran Gastroenterology Center
Winter Park, Florida, United States, 32789
United States, Michigan
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, United States, 48047
United States, Missouri
Midwest Center for Clinical Research
Lee's Summit, Missouri, United States, 64064
Center for Digestive & Liver Diseases, Inc
Mexico, Missouri, United States, 65265
United States, New York
Long Island Clinical Research Associates, LLP
Great Neck, New York, United States, 11021
Sponsors and Collaborators
Coronado Biosciences, Inc.
Layout table for additonal information
Responsible Party: Coronado Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT01434693    
Other Study ID Numbers: CNDO 201-002
First Posted: September 15, 2011    Key Record Dates
Results First Posted: May 20, 2013
Last Update Posted: May 20, 2013
Last Verified: April 2013
Keywords provided by Coronado Biosciences, Inc.:
T. suis ova
Crohn's disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases